Evidence map›Paper›PMID 41144631›Full record

Trial reportThe New England journal of medicine2026

Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years.

Martin B Leon, Michael J Mack, Philippe Pibarot, Rebecca T Hahn, Vinod H Thourani, S H Kodali, Philippe Généreux, Samir R Kapadia, David J Cohen, Stuart J Pocock and 12 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyComparative Study
PubMed Publisher
In one paragraph

Trial report in The New England journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02675114 (A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Who Have Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement), which is not on this map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02675114 naactive not recruitingnot on this map

A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Who Have Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement

TypeinterventionalSponsorEdwards LifesciencesRan2016 to 2029Enrolled1,000ConditionsAortic StenosisArmsSAVR, SAPIEN 3 THV
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Prosthesis-Patient Mismatch in All-Comer Patients Undergoing Newer-Generation Self-Expanding Transcatheter Aortic Valve Replacement.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Cerebrovascular Events in Aortic Stenosis: From Native Valve Disease to TAVR-Specific Risk and Prevention.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Martin B LeonColumbia University Irving Medical Center, New York-Presbyterian Hospital, New York.
Michael J MackBaylor Scott and White the Heart Hospital Plano, Plano, TX.
Philippe PibarotLaval University, Quebec, QC, Canada.
Rebecca T HahnColumbia University Irving Medical Center, New York-Presbyterian Hospital, New York.ORCID 0000-0003-1342-9191
Vinod H ThouraniPiedmont Heart Institute, Atlanta.
S H KodaliColumbia University Irving Medical Center, New York-Presbyterian Hospital, New York.
Philippe GénéreuxGagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ.
Samir R KapadiaCleveland Clinic, Cleveland.ORCID 0000-0002-0026-3391
David J CohenCardiovascular Research Foundation, New York.
Stuart J PocockCardiovascular Research Foundation, New York.
Yiran ZhangEdwards Lifesciences, Irvine, CA.
Molly SzerlipBaylor Scott and White the Heart Hospital Plano, Plano, TX.
Julien TernacleUnité Médico-Chirurgicale des Valvulopathies, Hôpital Haut-Leveque, CHU Bordeaux, Pessac, France.
S Chris MalaisrieNorthwestern University, Chicago.
Howard C HerrmannUniversity of Pennsylvania, Philadelphia.
Wilson Y SzetoUniversity of Pennsylvania, Philadelphia.
Mark J RussoRutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
Vasilis BabaliarosEmory University, Atlanta.
Tamim NazifColumbia University Irving Medical Center, New York-Presbyterian Hospital, New York.
John G WebbSt. Paul's Hospital, University of British Columbia, Vancouver, Canada.
Raj R MakkarCedars-Sinai Medical Center, Los Angeles.
PARTNER 3 Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFive-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, outcomes were similar among patients who had undergone transcatheter aortic-valve replacement (TAVR) and those who had undergone surgical aortic-valve replacement. Longer-term assessments of clinical outcomes and valve durability are needed.

methodsPatients were randomly assigned in a 1:1 ratio to undergo transfemoral TAVR or surgery. The first primary end point was a nonhierarchical composite of death, stroke, or rehospitalization related to the procedure, the valve, or heart failure. The second primary end point was a hierarchical composite of death, disabling stroke, nondisabling stroke, and the number of rehospitalization days related to the procedure, the valve, or heart failure, analyzed with the use of a win ratio analysis. Clinical, echocardiographic, valve-durability, and health-status end points were assessed through 7 years.

resultsA total of 1000 patients underwent randomization. In the analysis of the first primary end point, the Kaplan-Meier estimate of the incidence of an end-point event was 34.6% with TAVR and 37.2% with surgery (difference, -2.6 percentage points; 95% confidence interval [CI], -9.0 to 3.7). The win ratio for the second primary end point was 1.04 (95% CI, 0.84 to 1.30). In the TAVR and surgery groups, respectively, the Kaplan-Meier estimates for the incidence of components of the first primary end point were as follows: death, 19.5% and 16.8%; stroke, 8.5% and 8.1%; and rehospitalization, 20.6% and 23.5%. The mean (±SD) aortic-valve gradients assessed by echocardiography at 7 years were 13.1±8.5 mm Hg after TAVR and 12.1±6.3 mm Hg after surgery. The percentage of bioprosthetic valves that failed was 6.9% in the TAVR group and 7.5% in the surgery group. Patient-reported outcomes were similar in the two groups.

conclusionsAmong low-risk patients with severe, symptomatic aortic stenosis, no significant differences with respect to two primary composite end points involving death, stroke, and rehospitalization were observed at 7 years between those who had undergone TAVR and those who had undergone surgery. (Funded by Edwards Lifesciences; PARTNER 3 ClinicalTrials.gov number, NCT02675114.).

Indexed as

Aortic ValveAortic Valve StenosisHeart Valve Prosthesis ImplantationPostoperative ComplicationsTranscatheter Aortic Valve ReplacementAgedAged, 80 and overFemaleFollow-Up StudiesHeart FailureHeart Valve ProsthesisHumansIncidenceKaplan-Meier EstimateMalePatient Readmission

Identifiers

PMID41144631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.